Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Upcoming novel treatments for hidradenitis suppurativa: An overview of the pipeline. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmcp1014163
10.1056/nejmcp1014163 · External reference
10.1001/jamadermatol.2017.0201
10.1001/jamadermatol.2017.0201 · External reference
10.1056/nejmoa1504370
10.1056/nejmoa1504370 · External reference
10.1111/jdv.12966
10.1111/jdv.12966 · External reference
10.2340/00015555-2503
10.2340/00015555-2503 · External reference
10.1111/exd.14214
10.1111/exd.14214 · External reference
10.1016/j.jid.2021.02.742
10.1016/j.jid.2021.02.742 · External reference
10.1111/bjd.15748
10.1111/bjd.15748 · External reference
10.1111/jdv.18632
10.1111/jdv.18632 · External reference
10.1111/jdv.18163
10.1111/jdv.18163 · External reference
10.1111/bjd.13270
10.1111/bjd.13270 · External reference
10.1007/s13555‐025‐01487‐y
10.1007/s13555‐025‐01487‐y · External reference
Unresolved reference
External reference
10.1016/j.jaad.2025.05.878
10.1016/j.jaad.2025.05.878 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1007/s40259‐024‐00687‐w
10.1007/s40259‐024‐00687‐w · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1016/j.jaad.2026.04.781
10.1016/j.jaad.2026.04.781 · External reference
10.3390/biom14020175
10.3390/biom14020175 · External reference
10.1093/bjd/ljad225
10.1093/bjd/ljad225 · External reference
Lutikizumab in adults with moderate to severe hidradenitis Suppurativa after anti‐TNF therapy failure: a phase 2 randomized clinical trial
2026 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1016/j.jaad.2024.12.046
10.1016/j.jaad.2024.12.046 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1016/j.jaad.2025.10.149
10.1016/j.jaad.2025.10.149 · External reference
Unresolved reference
External reference
10.1016/j.jaad.2025.10.015
10.1016/j.jaad.2025.10.015 · External reference
Unresolved reference
External reference
10.1016/j.jaad.2025.05.1142
10.1016/j.jaad.2025.05.1142 · External reference
10.3390/ijms24043391
10.3390/ijms24043391 · External reference
Safety and efficacy of Deucravacitinib in moderate to severe plaque psoriasis for up to 3 years
10.1001/jamadermatol.2024.4688 · 2024 · External reference
Unresolved reference
External reference
10.1021/acs.jmedchem.3c00600
10.1021/acs.jmedchem.3c00600 · External reference
10.1016/j.jid.2025.05.014
10.1016/j.jid.2025.05.014 · External reference
10.3390/ijms21228436
10.3390/ijms21228436 · External reference
10.3390/ijms24098428
10.3390/ijms24098428 · External reference
Unresolved reference
External reference
10.1111/jdv.70118
10.1111/jdv.70118 · External reference
10.1016/s0140-6736(24)02475-9
10.1016/s0140-6736(24)02475-9 · External reference
10.1016/j.jacig.2025.100483
10.1016/j.jacig.2025.100483 · External reference
Dipeptidyl peptidase‐1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial
10.1186/s12931-023-02444-z · 2023 · External reference
Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil‐mediated inflammatory disease
10.3389/fimmu.2023.1239151 · 2023 · External reference
10.1126/scitranslmed.aav5908
10.1126/scitranslmed.aav5908 · External reference
10.1111/ijd.17706
10.1111/ijd.17706 · External reference
Unresolved reference
External reference
The role of the interleukin‐36 axis and mechanism of action of spesolimab
10.3389/fimmu.2023.1292941 · 2023 · External reference
10.1111/bjd.16019
10.1111/bjd.16019 · External reference
10.1056/nejmoa2111563
10.1056/nejmoa2111563 · External reference
10.1016/s0140-6736(23)01378-8
10.1016/s0140-6736(23)01378-8 · External reference
10.1093/bjd/ljae144
10.1093/bjd/ljae144 · External reference
Unresolved reference
External reference
10.3390/biomedicines10061303
10.3390/biomedicines10061303 · External reference
10.1681/asn.0000000526
10.1681/asn.0000000526 · External reference
10.1007/s13730‐025‐00991‐6
10.1007/s13730‐025‐00991‐6 · External reference
LB791 Avacopan, a highly selective small molecule inhibitor of c5a receptor, in patients with hidradenitis suppurativa: initial results from a randomized, double‐blind, placebo‐controlled, phase 2 study (aurora)
10.1016/j.jid.2021.07.121 · 2021 · External reference
10.1177/01926233221100168
10.1177/01926233221100168 · External reference
10.1016/s0140-6736(24)01211-x
10.1016/s0140-6736(24)01211-x · External reference
10.1016/j.jocn.2023.11.013
10.1016/j.jocn.2023.11.013 · External reference
10.1136/rmdopen-2025-005557
10.1136/rmdopen-2025-005557 · External reference
10.1177/15209156251396115
10.1177/15209156251396115 · External reference
10.3390/pharmaceutics17010091
10.3390/pharmaceutics17010091 · External reference
10.1111/bjd.21744
10.1111/bjd.21744 · External reference
10.1111/jdv.20222
10.1111/jdv.20222 · External reference
10.1016/j.jaad.2018.06.046
10.1016/j.jaad.2018.06.046 · External reference
10.1016/j.ejmech.2024.116562
10.1016/j.ejmech.2024.116562 · External reference
10.1007/s40265‐022‐01764‐6
10.1007/s40265‐022‐01764‐6 · External reference
10.1111/bjd.20880
10.1111/bjd.20880 · External reference
10.3389/fimmu.2023.1128897
10.3389/fimmu.2023.1128897 · External reference
10.1001/jamadermatol.2023.4800
10.1001/jamadermatol.2023.4800 · External reference
10.1007/s12016‐026‐09152‐8
10.1007/s12016‐026‐09152‐8 · External reference
10.1016/s2468‐1253(25)00071‐8
10.1016/s2468‐1253(25)00071‐8 · External reference
10.1111/imr.12621
10.1111/imr.12621 · External reference
10.1016/j.immuni.2013.11.010
10.1016/j.immuni.2013.11.010 · External reference
Hidradenitis Suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model
10.3389/fimmu.2018.02965 · 2018 · External reference
10.1371/journal.pone.0203672
10.1371/journal.pone.0203672 · External reference
10.1001/jamadermatol.2021.4926
10.1001/jamadermatol.2021.4926 · External reference
High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin‐2 expression
2022 · External reference
10.1016/j.jaad.2021.07.035
10.1016/j.jaad.2021.07.035 · External reference
10.3390/ijms242317014
10.3390/ijms242317014 · External reference
